Central trained immunity in the context of bladder cancer immunotherapy
Research output: Contribution to journal › Comment/Debate › Contributed › peer-review
Contributors
Abstract
Two articles in Immunity and Cancer Cell describe that bladder cancer immunotherapy with Bacillus Calmette-Guerin (BCG) alone or in combination with β-glucan, another agonist of trained immunity (TRIM), involves reprogramming of bone marrow (BM) hematopoiesis. These findings provide additional evidence of the therapeutic potential of BM-mediated TRIM against cancer.
Details
| Original language | English |
|---|---|
| Pages (from-to) | 1394-1396 |
| Number of pages | 3 |
| Journal | Cancer cell |
| Volume | 43 |
| Issue number | 8 |
| Publication status | Published - 11 Aug 2025 |
| Peer-reviewed | Yes |
External IDs
| PubMed | 40614740 |
|---|